A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...
SAN DIEGO — Treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib in combination with venetoclax was associated with improved progression-free survival compared with ...
Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback